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ABO-incompatible and ABO-compatible kidney transplantation are equivalent in
terms of short-term graft and patient survival. This is thought to be the result of
ABO-incompatible graft accommodation, which occurs when anti-blood group
antibodies re-occur after transplantation but somehow do not yield their
detrimental effect. The underlying mechanism is unclear, but one of the
hypotheses is that this is the result of complement inhibition. Since virtually all
ABO-incompatible graft biopsies are C4d positive, this complement inhibition
must occur somewhere in the complement cascade after the formation of C4d has
already taken place, but where exactly is unclear. It is also unclear whether
complement inhibition is complete. Incomplete accommodation could explain
why recent studies have shown that long-term graft function in ABO-
incompatible transplantation is somewhat inferior to ABO-compatible kidney
transplantation.
AIM
To unravel the relationship between pre-transplant anti-ABO antibodies,
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complement activation, and long-term graft function.
METHODS
We included all 27 ABO-incompatible transplantations that were performed
between 2008 and 2013 at the Academic Medical Center Amsterdam and the
University Medical Center Groningen. For each ABO-incompatible
transplantation, we included four ABO-compatible controls matched by age, sex,
and transplantation date.
RESULTS
Graft and patient survival were not significantly different. The slope of kidney
function during five-year follow-up was also not significantly different, but ABO-
incompatible recipients did have a lower kidney function at three months
(creatinine clearance 58 vs 69 mL/min, P = 0.02, Modification of Diet in Renal
Disease 46 vs 52 mL/min/1.73 m2, P = 0.08), due to a high rate of early rejection
(33% vs 15%, P = 0.03), mostly T-cell mediated. Pre-transplant anti-ABO IgG titers
were positively correlated with C5b-9 staining, which itself was positively
correlated with the occurrence of T-cell mediated rejection. This may be the result
of concurrent C5a formation, which could function as a costimulatory signal for
T-cell activation.
CONCLUSION
Co-stimulation of T-cell activation by ongoing complement activation by anti-
ABO antibodies may be responsible for an impaired long-term graft function in
ABO-incompatible kidney transplantation.
Key words: ABO-incompatible; Kidney transplantation; Complement; Graft function;
Rejection
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: This retrospective case-control study was designed to unravel the relationship
between complement activation, pre-transplant anti-ABO antibodies, and renal graft
function. In this study, the slope of kidney function during a five-year follow up was not
significantly different compared to matched ABO-compatible transplant recipients, but
ABO-incompatible kidney transplant recipients did have a lower kidney function at three
months, due to a high rate of early T-cell mediated rejection. Based on several
complement staining results, we argue that this may be due to co-stimulation of T-cell
activation by ongoing complement activation by anti-ABO antibodies.
Citation: van Sandwijk MS, Klooster A, ten Berge IJ, Diepstra A, Florquin S, Hoelbeek JJ,
Bemelman FJ, Sanders JS. Complement activation and long-term graft function in ABO-




To combat the long waiting times of kidney transplantation there is a push to increase
deceased donation, for example by using organs from marginal donors, as well as
living donation[1].  Based on the  prevalence  of  ABO blood groups of  donors  and
recipients, approximately 30% of willing and otherwise appropriate kidney donor-
recipient pairs are estimated to be blood type incompatible and do not proceed to
living donor transplantation[2]. Paired kidney exchange is a strategy that helps some
ABO-incompatible patients to find a suitable donor, although the probability of a
match varies greatly depending on the blood type combination and sensitization
status[3].  For  example,  the  chances  for  ABO-incompatible  and  sensitized  non-O
recipients to find a possible match are around 60%, whereas ABO-incompatible O
recipients only have a 15% chance for a match[2]. It is estimated that an additional 10%-
20%  of  living  donor  kidney  transplantations  can  be  performed  through  the
implementation of an ABO-incompatible kidney transplantation program[4,5].
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ABO-incompatible  kidney  transplantation  is  precluded  by  the  presence  of
isohemagglutinins –antibodies formed against blood group A and/or B- leading to
hyperacute rejection and allograft loss. Blood group antigens are present not only in
blood,  but  are  also  expressed on renal  tubular  cells  and endothelium[6].  As  first
described by Alexandre et al[7], removal of isohemagglutinins through plasmapheresis
prior to ABO-incompatible kidney transplantation can prevent hyperacute rejection.
Their  work on ABO-incompatible  kidney transplantation in  the early  1980s  was
greatly expanded on in Japan, a country with very low rates of postmortal kidney
donation  due  to  religious  objections[8].  In  Japan,  it  was  customary  to  perform a
splenectomy prior to ABO-incompatible transplantation, but this practice has mostly
been  abandoned  after  the  introduction  of  rituximab  in  the  last  decade[9].  The
introduction  of  rituximab has  also  led  to  a  more  widespread adoption  of  ABO-
incompatible  kidney transplant  programs outside Japan.  In a  large series  of  101
European,  Australian  and  New  Zealand  centers  1420  ABO-incompatible
transplantations were compared to 1:1 matched ABO-compatible transplantations[10].
Three-year death-censored graft  survival (89.9%) and three-year patient survival
(95.6%) were not significantly different, but there was a slightly lower one-year ABO-
incompatible patient survival due to a higher rate of infections. In a large American
series comparing 738 ABO-incompatible kidney transplantations to 1:5 matched ABO-
compatible transplantations, a lower ten-year death-censored graft survival (76.1% vs
72.9% was found in ABO-incompatible kidney transplantations[11]. Ten-year patient
survival was comparable for both groups (75.1% vs 74.5%).
ABO-incompatible  kidney  transplantation  results  in  superior  long-term graft
survival when compared to kidney transplantation in HLA-sensitized recipients[12-15].
This is thought to be caused by accommodation, which occurs when anti-blood group
antibodies re-occur after transplantation but somehow do not yield their detrimental
effect[16].  The pathophysiology of accommodation is poorly understood. Proposed
mechanisms can be divided into adaptations in the graft and in the host. Possible
adaptations in the graft include diminished blood type expression in the graft[17] and
expression of protective genes[18]. Possible adaptations in the host include IgG subclass
switching[19],  an  increase  in  regulatory  B  and/or  T  cells[20],  and  complement
inhibition[21]. The complement inhibition hypothesis is especially intriguing in light of
the  well-known fact  that  almost  all  ABO-incompatible  kidney  biopsies  are  C4d
positive,  but  that  C4d-positivity  –  in  contrast  to  ABO-compatible  kidney
transplantation – is not a surrogate marker of antibody-mediated rejection[22].
C4d is a split product without known biological function that is produced when
activation of the classical or the lectin pathway results in the conversion of C4 into C3.
Because it  forms a  stable  bond to  the cells  in  the tissue where it  is  deposited,  it
remains visible as a footprint while antibodies dissociate over time[23]. Complement
inhibition in ABO-incompatible transplantation is thought to occur more distally in
the complement cascade, i.e., after the formation of C4d has already taken place, but
the exact mechanism is unknown.
The case-control study presented here was designed to elucidate the relationship
between the rate of kidney function decline, pre-transplant anti-ABO antibodies, and
complement  activation  in  ABO-incompatible  renal  transplantation.  Firstly,  we
investigated whether ABO-incompatible kidney transplantation is equivalent to ABO-
compatible kidney transplantation not only in terms of graft and patient survival, but
also in terms of kidney function and long-term rate of kidney function decline. Full
accommodation would imply that both groups are indistinguishable. Secondly, we




We conducted a retrospective case-control study in which we included all  ABO-
incompatible  transplantations  performed at  the  Amsterdam University  Medical
Centers, location AMC, and the University Medical Center Groningen between 2008
and 2013. For each ABO-incompatible transplantation, we included four matched
ABO-compatible controls. The matching procedure was done as follows: from all 469
ABO-compatible kidney transplantations that were performed between 2008 and
2013, we selected the transplantations scheduled six months prior or after an ABO-
incompatible transplantation in the same transplantation center. Within this group,
we selected the four kidney transplant recipients of the same gender who had the
smallest age difference with their ABO-incompatible counterpart.
All patients were treated according to standard clinical practice. All patient data
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were  obtained  and  analyzed  retrospectively  after  being  anonymized.  Patient
treatment and clinical outcomes were not in any way affected by their retrospective
inclusion in this study, implying that Institutional Review Board approval was not
required according to Dutch law.
ABO-compatible transplantation immunosuppression
ABO-compatible kidney transplant recipients received basiliximab (20 mg on day 0
and day 4) and intravenous prednisolone (50 mg twice daily on day 0 and day 1) as
induction therapy. Post-transplantation maintenance immunosuppression consisted
of  tacrolimus (target  levels  10-15  ng/mL in  the  first  six  weeks  and 6-10  ng/mL
thereafter), prednisolone 10 mg once daily, and mycophenolic acid (1000 mg twice
daily), with graduate tapering of immunosuppression after one year.
ABO-incompatible transplantation requirements and procedure
In order to be eligible for ABO-incompatible transplantation, patients had to have a
negative (HLA)-crossmatch with an ABO-incompatible donor and anti-ABO IgG titers
(measured twice)  not  exceeding 1:256.  All  ABO-incompatible  kidney transplant
recipients  received  a  single  dose  of  rituximab of  375  mg/m2  30  d  prior  to  their
scheduled  transplantation.  Maintenance  immunosuppression  consisted  of
prednisolone, tacrolimus and mycophenolic acid, in identical dosages as in ABO-
compatible transplantation. However, whereas ABO-compatible recipients started
maintenance immunosuppression on the day of transplantation, ABO-incompatible
recipients did so two weeks before kidney transplantation. Immuno-adsorptions were
started  one  week before  transplantation  using  an  antigen-specific  carbohydrate
column (Glycosorb®). At least four immuno-adsorption sessions were scheduled, with
the option of additional sessions until the target anti-ABO titer ≤ 1:8 was reached.
Intravenous immunoglobulins (500 mg/kg) were given just before transplantation.
After transplantation, three more immuno-adsorption sessions were performed.
Infection prophylaxis
Patients with a cytomegalovirus mismatch (recipient IgG negative and donor IgG
positive) received six months of valgancyclovir prophylaxis. In addition, all patients
were  prescribed  at  least  four  months  of  Pneumocystis  Jirovecii  prophylaxis
(trimethoprim/sulfamethoxazole).
Complement activation in ABO-incompatible indication and protocol biopsies
Protocol  biopsies  were  performed  one  year  after  ABO-incompatible  kidney
transplantation according to  standard clinical  practice.  Indication biopsies  were
performed at the discretion of the treating physician. Immunofluorescence staining
for C4d, C1q, C3c and C5b-9 on fresh frozen sections was made available for all ABO-
incompatible indication and protocol biopsies (15 each).
Endpoints
The primary endpoint of this study was rate of kidney function decline, measured as
the slope of estimated glomerular filtration (eGFR) by means of the Modification of
Diet  in  Renal  Disease  (MDRD)  equation  and  the  slope  of  creatinine  clearance.
Secondary endpoints were proteinuria, graft and patient survival,  biopsy proven
rejections, infections, malignancies and complement activation on all indication and
protocol biopsies of ABO-incompatible transplants.
Statistical analysis
For the primary endpoint (rate of kidney function decline), linear mixed models were
used to estimate the slope of  the MDRD and creatinine clearance for both ABO-
incompatible and ABO-compatible kidney transplant recipients. In case of graft loss,
an  eGFR of  10  mL/min/1.73  m2  and a  creatinine  clearance  of  10  mL/min were
imputed. Sensitivity analyses were run both with and without these imputations.
Graft and patient survival and rejection episodes were compared using Kaplan-Meier
analyses. Infections and malignancies were compared using chi-square tests. The
statistical  methods  of  this  study  were  reviewed  by  H.  Peters  Sengers,  senior
epidemiologist at Amsterdam University Medical Centers, location AMC.
RESULTS
Between 2008 and 2013, 27 ABO-incompatible transplantations were performed at
both centers. For each ABO-incompatible transplantation, we included 4 matched
ABO-compatible transplantations at both centers, so that the total number of patients
included in our analysis equals 135.
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The  baseline  characteristics  are  described  in  Table  1.  The  groups  were  well-
matched, except for a lower percentage of related donors in the ABO-incompatible
group, which did not result in a higher number of HLA-mismatches. Panel-reactive
antibodies were low and not significantly different between both groups. Tacrolimus
trough levels were also not significantly different between the two groups except for a
slightly higher trough level at week six (Figure 1).
Kidney function
Linear  mixed  models  were  used  to  estimate  the  slope  of  eGFR  and  creatinine
clearance with and without imputation of 10 mL/min for graft  loss.  As Figure 2
indicates,  ABO-incompatible  kidney  transplant  recipients  had  a  slightly  but
significantly lower kidney function at three months, but the slope over time was not
significantly different. There was also no significant difference in proteinuria, which
was 0.20 g/d at three months and at five years in both groups (P  = 0.94 and 0.86,
respectively).
Graft and patient survival
Graft and patient survival (Figure 3) were not significantly different, although there
was  a  trend toward  a  slightly  lower  death-censored  graft  survival  in  the  ABO-
incompatible group (one-year graft survival 92% vs 99%, P = 0.65, compared to 83% vs
91% five-year graft survival, P = 0.12).
Biopsy results
Table 2 shows the results of both the indication and the protocol biopsies.  ABO-
incompatible kidney transplant recipients had a higher incidence of rejection (33% vs
15%, P = 0.03), mostly T-cell mediated. Antibody-mediated rejection rates were low in
both groups.  Donor-specific  antibodies  were  low and not  significantly  different
between both groups. Figure 4 (left-hand panel) shows that all ABO-incompatible
rejections  occurred  very  early  after  transplantation,  whereas  ABO-compatible
rejections occurred more gradually over time. In the right-hand panel of Figure 4,
ABO-incompatible and ABO-compatible transplantations are split based on whether
they experienced a rejection episode or not. This graph clearly indicates that early
rejection results in a lower kidney function at three months in ABO-incompatible
transplantation (P < 0.001). The slopes of all curves are not significantly different,
although there was a trend toward steeper curves for both ABO-compatible and ABO-
incompatible recipients with a rejection.
Figure 5A-C contain the results of immunofluorescence staining for C4d, C1q, C3c,
and C5b-9. As can be seen by comparing Figure 5A and B, the complement staining
results were quite equivocal for indication and protocol biopsies, except for C5b-9
staining, which was significantly more intense in indication biopsies (P = 0.04). In
addition, there was a significant correlation between pretransplant anti-ABO IgG
titers and peritubular C5b-9 in indication biopsies (correlation coefficient 0.72, P =
0.002),  as  well  as  a  significant  correlation  between C5b-9  and the  occurrence  of
rejection (correlation coefficient 0.52, P = 0.016). As expected in ABO-incompatible
biopsies, there were no significant correlations between C4d and the occurrence of
rejection.
Infections and malignancies
Bacterial  and viral  infections occurred more frequently in the ABO-incompatible
group (1.7 compared to 1.0 median infections per patient,  P  = 0.004, Table 3).  As
shown in Table 4, malignancies were also more likely to occur, with 22.2% of ABO-
incompatible patients diagnosed with a (pre)malignancy compared to 7.4% in the
ABO-compatible group (P = 0.01). This number should be interpreted with caution
however, as ABO-incompatible patients with a malignancy were on average 10 years
older than their counterparts without a malignancy. Also, ABO-compatible patients
tended to have more severe malignancies,  with 38% of ABO-compatible patients
diagnosed with a malignancy dying from their disease compared to 0% in the ABO-
incompatible group.
DISCUSSION
In this two-center case-control study, ABO-incompatible kidney transplant recipients
had a lower kidney function three months after transplantation compared to ABO-
compatible recipients, but the slope of kidney function over time was not significantly
different.  We have shown that the reason for this lower kidney function at three
months was a higher rate of early mostly T-cell mediated rejections, all occurring very
early  after  ABO-incompatible  transplantation.  Remarkably,  antibody-mediated
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Table 1  Patient and donor characteristics
ABO-incompatible (n = 27) ABO-compatible (n = 108) P value
Patient and donor characteristics
Recipient age (yr) 51.6 ± 12.3 51.7 ± 11.6 0.95
Donor age (yr) 53.6 ± 12.1 52.7 ± 12.4 0.73
Recipient gender (% male) 63 63 1.00
Donor gender (% male) 63 44 0.07
Related/unrelated donors (% related) 26 51 0.02
Donor MDRD (mL/min/1.73m2) 96.6 ± 20.5 93.3 ± 18.4 0.42
HLA mismatches (A/B/DR) 3.5 ± 1.6 3.2 ± 1.7 0.48
Mean follow-up patient (yr) 3.7 ± 1.7 3.7 ± 1.6 0.98
Underlying renal disease 0.57
Glomerulonephritis, (%) 30 27
Hypertensive disease, (%) 7 18
Diabetic nephropathy, (%) 4 7
Cystic kidney disease, (%) 33 19
Urological disease, (%) 7 8




AB → O, (%) 0
B →A, (%) 11
A→ B, (%) 7
AB→ A, (%) 4
AB → B, (%) 4
Median pre-treatment IgG anti-A/B titer 1:64 (1:6-1:128)
Median pre-treatment IgM anti-A/B titer 1:8 (1:2-1:28)
Panel reactive antibodies (% positive) 9 7 0.60
Previous renal replacement therapy
First transplantation (%) 89 94 0.30
Pre-emptive transplantation (%) 44 53 0.44
Non pre-emptive (%) 56 47 0.83
Haemodialysis (%) 34 26
Peritoneal dialysis (%) 22 21
Months on dialysis 22 (9-26) 16 (11-27) 0.41
Ischemia times
Cold ischemia time (min) 161 ± 84 155 ± 59 0.49
Second warm ischemia time (min) 41 ± 27 40 ± 22 0.77
Delayed graft function (%) 8 4 0.37
All values as percentages, mean ± standard deviation or median and interquartile range. P values calculated with t-test, Mann-Whitney U test or chi-square
test  where  applicable.  Panel  reactive  antibodies  >  8% were considered positive.  HLA:  Human leukocyte  antigen;  IgG:  Immunoglobulin  G;  IgM:
Immunoglobulin M; MDRD: Modification of diet in renal disease.
rejection rates were low in both groups. Tacrolimus levels were not significantly
different  for  most  of  the  follow-up  period  and  are  thus  not  responsible  for  the
difference in kidney function.
The  high  rate  of  early  mostly  T-cell  mediated  rejection  in  our  study  is  not  a
common finding in ABO-incompatible studies. It  may be due to the fact that our
standard protocol for ABO-incompatible transplantation does not include basiliximab,
which is widely used as induction therapy to prevent T-cell mediated rejection in
ABO-compatible transplantation[24]. There is no conclusive evidence available whether
adding basiliximab to ABO-incompatible induction protocols improves outcomes. In
the large series published by Opelz et al[10], 39% of centers had added basixilimab, 1%
gave anti-thymocyte globulin, and 60% gave neither. Death-censored graft survival
was not affected by the addition of basiliximab.
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Figure 1
Figure 1  Tacrolimus trough levels. Tacrolimus trough levels at 2 wk, 6 wk, 3 mo, and 1 year after transplantation.
Another explanation for the high rate of early mostly T-cell mediated rejection
could be complement activation. As discussed above, higher pre-transplant anti-ABO
IgG titers resulted in more intense C5b-9 staining in indication biopsies. C5b-9 is the
membrane  attack  complex,  which  is  formed  as  a  final  common  pathway  of  all
complement cascades and causes cell lysis. C5b-9 formation implies that complement
inhibition,  which  is  one  of  the  mechanisms  thought  to  be  responsible  for
accommodation  in  ABO-incompatible  kidney  transplantation,  is  incomplete.
Incomplete complement inhibition also results in C5a still  being formed in small
quantities. C5a is an anaphylotoxin that has long been known be able to stimulate
neutrophils, mast cells and macrophages. There is emerging evidence that C5a can
also function as a costimulatory signal for T-cell activation[25-29]. One could postulate
therefore  that  high  pre-transplant  anti-ABO  IgG  titers  result  in  high  levels  of
complement activation resulting in C5a-stimulated T-cell activation.
In  summary,  in  our  study  ABO-incompatible  and  ABO-compatible  renal
transplantation  have  a  similar  5-year  graft  and  patient  survival,  but  in  ABO-
incompatible transplant recipients,  kidney function is inferior compared to well-
matched  ABO-compatible  transplant  recipients.  This  may  be  due  to  anti-ABO
antibody  driven  ongoing  complement  activation  resulting  in  a  C5a-stimulated
increase in early T-cell mediated rejection. In other words, high pretransplant anti-
ABO  antibody  titers  could  result  in  incomplete  accommodation  of  the  ABO-
incompatible graft, especially in the absence of induction therapy with agents like
basiliximab. Further studies are needed to confirm this hypothesis.
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Table 2  Biopsy results
ABO-incompatible (n = 27) ABO-compatible (n = 108) P value
Treated rejections, (%) 33 15 0.03
Acute antibody mediated rejection, (%) 4 1 0.36
Acute T-cell mediated rejection, (%) 30 14 0.05
Grade IA, (%) 7 7
Grade IB, (%) 4 3
Grade IIA, (%) 15 3
Grade IIB, (%) 4 1
Grade III, (%) 0 0
Borderline acute T-cell mediated
rejection
4 7 0.50
Donor specific antibodies (% positive) 0 6 0.17
P values calculated with chi-square test. Donor specific antibodies were measured according to local practice, i.e., at the discretion of the treating physician,
and routinely at 8 wk after transplantation for Groningen patients and yearly for Amsterdam patients.
Table 3  Infectious complications
ABO-incompatible (n = 27) ABO-compatible (n = 108) P value
Total no. of infectious complications per patient 1.7 (1-2.3) 1.0 (0-2) 0.004
CMV infections, (%) 12 11
EBV infections, (%) 0 3
BK infections, (%) 15 6
Other viral infections, (%) 31 9
First urinary tract infection, (%) 38 30
Recurrent urinary tract infections, (%) 8 11
Other bacterial infections, (%) 23 7
Other infections, not otherwise specified, (%) 31 20
All values as percentages or median and interquartile range. P  values calculated Mann Whitney U  test or chi-square test where applicable. CMV:
Cytomegalovirus; EBV: Epstein Barr virus.
Table 4  Malignancies
ABO-incompatible (n = 27) ABO-compatible (n = 108) P value
% of patients with a (pre)malignancy 22.2 7.4 0.01
Solid organ, (%) 11 2.8
Lymphoma, (%) 0 1.9
Skin malignancy, (%) 3.7 1.9
Melanoma, (%) 3.7 0
Premalignant lesion, (%) 3.7 0.9
% of patients dying from their malignancy 0 38 0.09
P values calculated with chi-square test.
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Figure 2
Figure 2  Kidney function. A: Estimated glomerular filtration rate (Modification of Diet in Renal Disease) without imputation in case of graft loss; B: Estimated
glomerular filtration rate (Modification of Diet in Renal Disease) with imputation of 10 mL/min/1.73 m2 in case of graft loss; C: Creatinine clearance without imputation
in case of graft loss; D: Creatinine clearance with imputation of 10 mL/min/1.73 m2 in case of graft loss. Curves were estimated using linear mixed models. The dots
indicate point estimates at 3, 6, 12, 24, 36, 48 and 60 months. CrCl: Creatinine clearance; MDRD: Modification of Diet in Renal Disease.
Figure 3
Figure 3  Patient and graft survival. A: Patient survival; B: Death-censored graft survival.
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Figure 4
Figure 4  Rejection-free survival and kidney function split by occurrence of rejection. A: Rejection-free survival; B: Estimated glomerular filtration rate
(Modification of Diet in Renal Disease). P value calculated for intercept of ABO-i recipients with rejection (black line) compared to all other groups.
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Figure 5
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Figure 5  Complement activation in ABO-incompatible. A: Complement activation in ABO-incompatible indication biopsies; B: Complement activation in ABO-
incompatible protocol biopsies; C: Digital photographs of complement activation. Intensity of staining ranges from 0-3. Figures indicate the percentage of biopsies with
each intensity score. Glom: Glomerular; PTC: Peritubular capillaries; BMt: Basal membrane of the tubuli.
ARTICLE HIGHLIGHTS
Research background
Short-term graft and patient survival in ABO-incompatible kidney transplantation are equivalent
to ABO-compatible kidney transplantation, but in ABO-incompatible kidney transplantation,
ongoing activation of complement by anti-ABO antibodies might adversely affect long-term graft
function.
Research motivation
We aimed to investigate whether ongoing complement activation in ABO-incompatible kidney
transplantation could explain why long-term graft function is impaired in ABO-incompatible
kidney transplantation compared to ABO-compatible kidney transplantation.
Research objectives
To measure long-term graft function in all ABO-incompatible kidney transplantation recipients
at the Academic Medical Center Amsterdam and the University Medical Center Groningen,
compare this to long-term graft function in matched ABO-compatible kidney transplantation
recipients and relate this to various markers of complement activation.
Research methods
We  used  linear  mixed  models  to  estimate  long-term  graft  function  decline  in  both  ABO-
incompatible and matched ABO-compatible kidney transplantation recipients. Matching criteria
were age, sex, and transplantation date. AB O-incompatible kidney biopsies were stained for
various markers of complement activation.
Research results
The slope of kidney function during five-year follow-up was not significantly different between
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ABO-incompatible and ABO-compatible kidney transplantation, but ABO-incompatible kidney
transplant recipients did have a lower function at three months after transplantation due to a
high  rate  of  early  mostly  T-cell  mediated  rejection.  Rejection  and  C5b-9  activation  were
positively correlated.
Research conclusions
Ongoing complement activation adversely affects long-term graft function in ABO-incompatible
kidney transplantation. We hypothesize that this may be due to concurrent C5a formation,
which functions as a costimulatory signal for T-cell activation.
Research perspectives
Further studies are needed to confirm whether ongoing C5a formation is responsible for T-cell
mediated rejection in ABO-incompatible kidney transplantation.
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